Core Insights - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system cancers [2] - The company will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8 to 10, 2025 [1] - Dr. Marc H. Hedrick, President and CEO of Plus Therapeutics, will engage in a fireside chat at the conference, available on demand for registered investors starting September 5 [2] Company Overview - Plus Therapeutics is headquartered in Houston, Texas, and specializes in targeted radiotherapeutics aimed at difficult-to-treat CNS cancers [2] - The company is advancing a pipeline of product candidates, with lead programs targeting leptomeningeal metastases and recurrent glioblastoma [2] - Plus Therapeutics has established a supply chain through strategic partnerships to support the development, manufacturing, and potential commercialization of its products [2]

Core Insights - Palisade Bio announced positive topline results from Phase 1 studies of PALI-2108, a PDE4 B/D inhibitor for fibrostenotic Crohn's disease and ulcerative colitis [1][2] - The study met primary endpoints of safety, tolerability, and pharmacokinetics, supporting progression to Phase 2 development [2][3] Safety & Tolerability - No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs were observed across SAD, MAD, and food effect cohorts [7] - In the SAD study (15–450 mg), only mild and reversible TEAEs occurred, limited to the highest dose [7] - The MAD cohorts showed mostly minor TEAEs, with the 15 mg BID dose free of any TEAEs [7] Pharmacokinetics - PALI-2108 achieved therapeutically relevant concentrations in colon tissue up to 24 hours post-dose, confirming its targeted profile [7] - Plasma-to-tissue ratios indicated localized drug activation in the distal gut with low systemic exposure [7] - Population PK modeling supports a therapeutic window aligned with observed safety and tolerability [7] Future Development Plans - Based on the results, Palisade Bio plans to initiate a Phase 1b cohort to further explore safety, tolerability, and pharmacokinetics while completing chronic safety studies [8] - Phase 2 clinical programs will assess PALI-2108's efficacy, safety, and tolerability in patients with fibrostenotic Crohn's disease and moderate to severe ulcerative colitis [8]

TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on January 17, 2024. Registration No. 333-276467 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRANSCODE THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) | Delaware 2834 | | 81-1065054 | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorp ...

TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on September 22, 2023. Registration No. 333-274251 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRANSCODE THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 81-1065054 (Primary Standard Industrial Classification Code Number) ...

TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on September 8, 2023. Registration No. 333-274251 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRANSCODE THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) AMENDMENT NO. 1 TO Delaware 2834 81-1065054 (I.R.S. Employer Identification No.) (State or other jurisdiction of incorporation or organization) (Primary Standard Ind ...